Q4 2019 Earnings Call
Good morning, ladies and gentlemen, thank you for standing by welcome to the Invacare fourth quarter in full year 2019 conference call webcast.
The management overview.
Well open the call for questions.
That's true.
Analysts interested in asking questions. When you did island of questions cannot be submitted via the webcast.
The first part of the call all four mines have been placed on mute.
This conference is being recorded Monday February 10th 2020.
Now I would like to turn the call over June largely Invacares director of Treasury and Investor Relations. Please go ahead.
Thank you Jay joining me on todays call from <unk>.
<unk>, Chairman, President and Chief Executive Officer.
You're right.
Sure.
He will be reviewing our 44 three full years 29.
Right.
Update on the transformation.
The best is how long we agreed to coffee this month.
But it was pretty linear.
We're webcasts <unk> presentations, we will refer to during todays presentation.
Karen.
<unk> Investor Relations.
Further information can be found <unk>.
He's going back again I'd like to note that during today's call may make forward looking statements. All the company if I didn't nature address matters that are uncertain.
Actual future results may differ materially from those expressed in or statements today due to various uncertainties never for either the cautionary statement included on the second page of our webcast slides on our fourth quarter earnings release.
Well nation is considered to be non-GAAP financial information there will be discussed on todays call such in constant currency net sales.
Currency I'm kidding free cash flow adjusted EBITDA and adjusted net loss. He didnt dosing is kinda or webcast like India related reconciliations.
We posted on our website.
I'll now turn the call agreements Arnie.
Thanks, Good morning, everyone on today's call.
We could see because its 2019 on screen continued to build.
And since earlier in your include the business. She is working on it because.
Okay I get into our results I want to take time to reflect on our progress each one go to you.
That's a heavy 2020.
Turning to slide four in 2019 is critical for us.
Getting results in cash flow and take another significant step towards our long term targets.
I used to industry cheaper guidance is generating at least $20 million with adjusted EBITDA and concern me not more than 25, new dog and cat.
Full year 2019 for total operating loss improved by 43%.
Adjusted EBITDA was $20.7 million isn't improvements of more than $22 million compared to 23, driven by actions, we streamlined business operation.
A few days an expanded goes from.
Importantly, or North America doesn't strike it was 77% improvement in operating performance.
Free cash flow using benefited from stronger operating results.
Working capital primarily from lower inventory levels, which led to mean 45 million dollar improvement compared to 20 team.
So what can you give me $1 million, some cash compared to having consumed and 53 million dogs and cats and prior year.
Well I'm encouraged by our country progress he didn't achieve everything set up students when the team isn't it feels good fell short of our expectation.
Reach their full potential we will need price since group and 2020, not many actions already underway to help us to that.
Turning to slide five are strong 2019 full year performance was driven by key initiatives focused on product innovation sales mix.
Process in prison and expanding balance sheet flexibility.
Turning to product innovation and sales mix, you made significant adjustments to our portfolio I discontinuing certain legacy wheelchairs and whitestone product.
Thing I'm more valuable products isn't a respiratory portfolio and introducing new products in all categories, this offering greater customer and clinical benefit.
It was all these actions will decline that's less than one person constant currency net sales.
Willingly as a result was a weakness in the respiratory market early in 2019 and future intentional decisions in the second half.
It's declined more than enough that $10 million grocers mobility and seating.
Even despite the significant restaurant sales decline for the year financial results for the respiratory product lines increased due to favorable mix optimize cost.
Uhhuh industry, leading product reliability.
The company's gross profit improved by seven basis points.
For the last several years, we've been focusing on building back our mobility and seating.
2019, or global mobility and seating portfolio at constant currency net sales grew by $10 million were 2.5 per cent for changes in the man power portfolio worldwide.
In Europe mobility and seating constant currency net sales grew 4.4%, that's resulting strong sales of the smooth power Adam.
In North America mobility, and seating girls I wouldn't go the product is overshadowed by the year long impacted discontinued.
Anyone sure.
Importantly, despite lower sales in North American trouble regions gross profit improved by 200 basis points.
In the prior year.
Product development teams continue to strengthen our portfolio 2019 wants you products in every product category power and made a wheelchair respiratory lists and mattresses, all which will help us drive incremental sales in 2020 them beyond its adoption grows.
Fourth quarter 2019 viewed very competitive center will drive power wheelchair dealing capability.
Outstanding kinetic and specifically designed for Threed reimbursements in the United States. So more people can be fun for this basically.
Well, let him short time are you seeing system has been in the market. It has been well received by customers in a new users.
And it shouldn't be launched the smooth our head on in Europe, which adds amazingly small agile and intuitive lithium battery powered propulsion to many wheelchairs.
Various regions, we added products, where lifestyle segment can you give me that system.
And flooding and in light of pneumatic mattresses for care for patients with friends and tissue condition.
Sales is easy product since then globally in 20 Twond.
Finally in respiratory we introduced the world's first portable oxygen concentrator with remote control meeting is new wireless technology was born of getting clients the world.
Hands free battery powered portable oxygen concentrator. So people can continue living actively independently that's tough.
We expect these innovative new product to grow our business I completely agree to clinical studies and users can even better financial options for our customers.
Yeah, I'm driving innovation, we made substantial business improvements in 29 team, we streamlined our business to reduce cost increased competitiveness improved profitability.
Particularly.
<unk> constant currency, that's you need by nearly $15 million.
He mitigated the potential $7 million exactly tariff.
Completed two plant consolidations in Europe that had been announced in 20 feet.
And in December we announced the beginning of an additional large plane transfer your.
Consolidated our team in German operations into a single German facility, but again, it's 2020.
Additionally, the beginning of fourth quarter, we engaged in a strategic long term program to modernize their infrastructure.
Central to our continued business improvements for the benefit of customers suppliers and shareholders.
As previously discussed this novel arrangement will enable us to execute the complete renovation to where I see infrastructure.
No incremental any period expense compared to our capital spend.
Once completed we will have a robust customer self service platforms, which will simplify how customers transact with us.
Improved customer experience with all the modern conveniences typical ecommerce site.
But there will also provide stated the art manufacturing inventory function in a simplified reporting system.
She system will enable further streamlining the business and ultimately better financial performance.
We have a track record of managing through diversity is delivering meaningful improvement in 2020, we will continue to look for additional ways to optimize.
Finally in 2019 also improved our capital structure and strengthened our balance sheet.
Quarter 20 that teams reviews, the total amount of debt outstanding by repurchasing $16 million of convertible notes at a discount to par and in fourth quarter 2019, we extended the maturity, but the balance of the 2021 convertible notes to a new maturity date of November 2024 at the same interest rate.
The actions enhance our financial flexibility as we continue or that business transformation.
Right and proper accomplishments in the past some years and definitely it doesn't 2019.
2020 people go further on these initiatives to realize their long term goal.
Turning to slide six the strong foundation laid in 2019 allows us to focus on execution 2020.
One of my teams, we launched many new innovative product several years minutely weren't as affected commercializing them as we'd expect.
In 2020 actions in place to rectify that stand to accelerate sales growth by investing in sales and marketing Carolyn making our product launch programs more consistent increasing the number of demo units.
Driving customer awareness and reallocating spending to all of this was still lowering overall sense you make sense.
In mobility and seating, we will launch or new lying in front wheel drive and rear wheel drive power wheelchairs. During the first half of 2020, supplementing the power wheelchair standing capabilities launch in the fourth quarter 2019.
Based on the tiny these new product launches in the long order cycle, we expect the financial benefit, but these new products later in the year.
Sales in first quarter 2020 are expected to be flat compared to first quarter 2019, and sales should accelerate throughout the year in line typical seasonality of our business.
Looking ahead, we continue to expect interest in our entire respiratory portfolio.
The second half of 20 to 23 to begin launching a refreshed portfolio stationary oxygen concentrators with improved performance novel features and the new levels of low total ownership costs are providers.
Universally we're seeing respiratory customers, making value based choices that reflects an appreciation of total cost of ownership, which is good for into care branded products.
We remain committed to serving the respiratory markets and are confident the business has a bright future.
During the process improvements will begin to realize the full years benefits of the plant consolidations in France, and the cost saving actions that occurred in 2019.
20 were focused on the consolidation of two German manufacturing facility, which is expected to generate annual pre tax.
Pretax cost savings of approximately $5 million when completed in the fourth quarter.
In addition, we plan to reduce global freight cost by partnering with third party logistics provider, which will improve customer service and further extends as profit.
Finally, the successful modernization of our IP infrastructure will improve customer engagement increased visibility it will be sales trends and inventory levels and streamlined operations, all which will strengthen our financial performance.
We expect minimal disruption as we go live in North America in 2020 and go live in Europe in 2021.
In summary, we have all the necessary building blocks in place for.
[laughter] for a successful 20, twond and I'm confident in our ability to deliver sustained and improved performance.
I'll now turn the call it the cat Linehan to discuss the performance in the second and additional financial results for fourth quarter and full year.
Thanks, Matt turning to slide eight during the fourth quarter constant currency net sales decreased 2.1%, primarily driven by a decline in respiratory products.
Gross profit improved 130 basis points with growth across all segments, primarily as a result, a favorable sales mix and lower material costs.
Actually offset by unfavorable manufacturing variances and foreign exchange.
Absent currency has seen a improved by 4.1% or $2.7 million driven primarily by previously announced restructuring actions, partially offset by an increase in stock compensation and bonus expense.
Operating Watson $3.8 million compared to a loss of 1.1 billion in the fourth quarter 2018, as a reduction of 3.9 billion and asking expenses.
More than offset by an increase of 6.4 million of restructuring costs, primarily related to the German plant consolidation and high T. outsourcing.
Free cash flow improved by more than 200% for $3.8 million and adjusted EBITDA was $13.9 billion and improvement of 7.9 million driven by lower SGN expenses.
Turning to slide nine for the full year mobility and seating constant currency net sales growth of $10 million is more than offset by an over 19 million dollar decrease in sales of respiratory products.
Excluding respiratory constant currency net sales increased 1.2%.
Gross profit improved 70 basis points, which reflects the effective mitigation or approximately 5 million appears leaving less than 2 million of remaining exposure.
Constant currency I've seen a improved by nearly $15 million due to restructuring actions taken throughout the year.
Free cash flow improved by nearly $45 million or approximately 85% driven by stronger operating result in reduced working capital.
Adjusted EBITDA was $28.7 million, an improvement of over 22 million demonstrating that our transformation remains on track.
Turning to slide 10, your constant currency net sales decreased slightly to do minor decreases in all product categories.
Well, we believe the markets in Europe are healthy.
Variance slowness in Denmark, and equipment sales given the government's focus on refurbishment of product versus investing in new product.
In addition, lower sales of lifestyle products in Sweden, where the results of US a day and the timing of a tender being awarded.
However, operating income increased by $4.4 million are almost 49%.
Principally due to improved gross profit from favorable material freight and manufacturing variances as well as reduced that's you named census.
These were partially offset by lower net sales.
Favorable foreign exchange of $900000.
For the full year constant currency net sales increased 1.2%.
The growth was driven by 4.4% increase and sale of mobility and seating products.
Merely due to the successful launch of the electro motive power add on products.
Operating income increased $3.5 million, despite the unfavorable impact from foreign exchange, a 3.2 million.
Turning to slide 11, North America constant currency net sales decreased 2.5%.
We achieved growth in mobility and seating products, that's 2.8% driven by increased sales of powered mobility products, but this is more than offset by decreases and other products, including a more than 20% decline in respiratory.
Excluding respiratory constant currency net sales increased 2.8%.
Gross profit improved 140 basis points and was positively impacted by favorable material and freight costs as well as improved sales mix, partially offset by unfavorable manufacturing variances.
Operating loss improved by over 96% or $7.2 million, primarily due to higher gross profit and reduce that see an extent.
For the full year constant currency net sales growth and mobility and seating and lifestyle, that's completely offset by decreases in respiratory.
Excluding respiratory constant currency net sales increased 8.1%.
Gross profit improved 200 basis points and was positively impacted by favorable material freight and salesmen.
Partially offset by unfavorable sales volumes and manufacturing variances.
Operating results improved significantly by nearly $25 million are almost 77% as we realize the benefit of transformation initiative, which expanded gross profit and reduced SGN expenses.
Turning to slide 12, Asia Pacific constant currency net sales decreased 14.5% driven by lower sales of mobility and seating product. He do payer process changes, which temporarily affected funding in New Zealand.
Operating loss for all other increased $8 million, primarily driven by increased Afghanistan related to stock compensation and bonuses as well as a decline in the operating profit for the Asia Pacific business, driven by lower net sales increased after an acre.
For the full year constant currency net sales increased 24%.
Operating loss increased 12.2 million principally due to the same factors that impacted the fourth quarter.
Moving to slide 13, the company generated free cash flow of $3.8 million.
The fourth quarter 29 scenes and improvement of 2.7 million driven by stronger operating results, partially offset by higher investments and capital expenditures.
As of December 31st 2019, the company had 254 million and convertible debt outstanding and $80 million of cash anesthesiology.
The revolving credit facility has remained undrawn for the last four years.
The company believes that continued generation as adjusted EBITDA, driven by operational performance cash balances on hand, and expected free cash flow will support the company's ongoing transformation plans and enable us to address future debt maturities.
Turning to slide 15 for the full year 2020, we expect operating results consisting of constant currency net sales growth of 2% to 4% for the full year.
Adjusted EBITDA of at least $45 million and free cash flow generation of at least $5 million. The company expects constant currency net sales growth in 2020 in combination with what is expected to be a cyclical here a seasonal sales variance by quarter.
As a result sales are expected to be flat in the first quarter 2020 over the prior year.
Gross coming in later quarters amplified by new product introductions expected to be impactful in the second half something here.
Adjusted EBITDA is expected to benefit from for their process improvements and cost reductions to with her through the year, mostly in the second half after precedent work is completed.
That compensation expense is expected to be similar to 29 team.
And finally free cash flow guidance assumes a significant improvement and segment operating performance compared to 2019, partially offset by increased working capital to support growth.
Especially in the North American mobility, and seating products with an extended quote to cash cycle.
We also anticipate higher capital expenditures and cash usage to fund restructuring actions, especially in the second half related to cost savings.
Free cash flow and the first quarter 2020 is expected to be similar to the first quarter 2019 and includes ERP related investments.
These operating results are in line with previous guidance for run rate adjusted EBITDA in the range of $85 million to $105 million by the fourth quarter 2020.
85 to 105 million dollar run rate is not intended to reflect our full year 2021 guidance, which we will provide stewart our fourth quarter 2020 earnings release.
I will now turn the call back over to now.
Thanks.
We made substantial durable improvements to our business and 29 team that resulted in significantly improved performance. We will continue to execute our plans returned the company to profitability and increase shareholder value.
The entire into care team of associates and I. Appreciate the continued support of our shareholders and I want to thank all of her immature associates, who worked so hard to make into care strong.
Thank you for taking time to sprint Nazi question.
And ladies and gentlemen, if he would like to ask a question you consider by pressing star one on your telephone keypad just keep in mind, if you're using a speaker for me should the need functions, where at least so that signal Curry tour equipment on once again star one for questions.
We will begin with Bob Labick with C.G.
Aries.
Good morning, congratulations on a every quarter.
Hi, great great job great execution.
So let's start with the purpose off the B.I.T. outsourcing in ERP implementation I'm, obviously, that's still a lot of head and you're on track. There can you just remind us of the road map or for the next six to 12 months and you know where we stand on.
Both of those things got the outsourcing and I'm at your peak.
Yeah, those clinical hand in hand really are in the process of turning over all of her I see infrastructure to Brazil itself. So that they provide that back to some service for the legacy systems and then at the same sign migrate from those legacy systems to new ERP systems, and it's not just the European lots of other software.
No, there's probably a can get through our dozens and dozens of elements of software that make a big enterprise work.
Weak objectives for our like reaching this year is to complete the transfer of existing I see.
Services to grilling sauces and at the same time to go lives in ERP system in North America.
The middle of this year, so that after the normal amount of hyper care and transition and getting to steady state we end up simplifying our business.
Easier to transact and a more profitable as result of that before the end of this year in North America.
Was that we're using to define our processes as a global template.
Team members from around the World are working on that now that simply once it's done in North America will be deployed in Europe at the beginning of next year and we have a few subsidiaries around the world that will catch up at various points when it makes sense, but the majority of North America will be no and Europe will be the beginning of next year.
Got it great and then I'm jumping over to new products.
Right.
Oh, that's going thanks, I'll go into new products, you talked about some.
New wheelchairs coming out this year can you talk a little more about hey, what differentiates them feature wise and then all sorts importantly from a reimbursement perspective, you highlighted a group three reimbursement just.
Hi, Matt if you count.
Sure.
So.
Mr is typically come into threed drives that varieties similar cars I guess, though front wheel drive near real time Center will drive for reasons that those different modalities are of relative importance, depending on a person's lifestyle, what you're doing it's usually a combination of how much outdoor indoor driving that.
Turning to do how big the spaces are operating in for living are working or socializing and how much harder socked ground, but they're trying to go on as a part of the normal day and there are different tradeoffs.
Probably and I'm going to estimate roughly 30% of the market worldwide, it's from yielding rear wheel drive and those are markets, where we either haven't had a modern product for a product that fall since the consent decree having not we refurbish start from the drug products.
Just 2014.
So getting these products back up and refreshed is really important for into care addressing.
Segment of the market, where we didnt have the best products until now.
Now we believe its products, we are bringing to market in those categories are top of the line in terms of performance and capabilities modern aesthetic and the king the metrics that help the occupancy was very smooth and seamless.
In the at the end of last year.
In the third quarter, we had a clearance for our standing system, which allows an occupancy come to a nearly vertical standing position than normal everybody would have.
All sorts of intuitive and clinical benefits you can imagine the social benefits as being high level with other people around but also bone strength is enhanced by willing bone cardiovascular strength is enhanced by having a greater vertical rises blood flow between the level at the heart feed and respiratory digested benefits occur also.
Not only was an important for us to come out with a great product that has agreed to the maddox, but it was important for us to come out with a chair design for the reimbursement system art shares uniquely designed for group three reimbursement, which is a level lower than the top competitors reimbursement level, which should mean, it's easier to get patients funding advisor.
Insurance carriers, because it's essential benefit we're very excited about having set out to do that from the beginning of the product and seeing that now available in the marketplace today.
So we shouldn't no compromise.
That's great and then just sticking with a wheelchair I know that you're the only thing or public Standalone company in the space, what maybe hard to speak about this but could you. If you can you discuss a little bit about the.
Position or your position on the four mirrors for some of the large real care providers out there some of your customers and how chain pallets stamps this year versus the last few years.
I think is going to be question. Bob is it's important for us to have our customers have access to our products. So that their sales and clinical teams can make them available to their clients and over the last four years or three years since the consent decree weve been working hard to balance our internal costs, which are getting better and better with what our customers need.
In order to hit their targets of deploying a products to their markets.
This year I think we have even better priced position he's done better and improving cost positions of our product and I think we have a lot of interest from all of our customers based on new product. So we expect things to be even better. This year, we had good relationships with all our customers worldwide and I think internally and externally. We're usually excited about the portfolio new products that.
All of us and all the clients out there worldwide, we're looking for mobility solutions.
Perfect all right. Thank you very much I'll get back in Q.
I think stuff.
Well now take our question and that will next question and that will come from Mike, Mike Matson Needham and company.
Hi, good morning, Thanks for taking my questions 'em horns ask about the.
I want to ask about the North American mobility and seating business I don't know if you can disclose what the growth was there if you strip out the discontinued products, but you know what the the powered wheelchairs.
No I I assume that salt significantly stronger growth during the month overall number ones.
Yeah. It would have been like see growth in the total segment was 2.8% we haven't really disclose.
The specifics of how much was coward versus mail, but as you noted on manual was down so the growth would definitely be higher than the 2.8%.
Okay. Thanks, Andrew we saw nice successful growth on the a standard.
The quarter.
[music].
Okay, and then you know the revenue guidance, it's good to see the 2% to 4% constant currency, but that's fairly significant step up for from where you are or were in 2018. So you know how what's your confidence level on the ability to deliver that especially considering that it seems like it's going to be more Hawaiian on what happens in the second half a year.
Okay.
Yes, it's a good question might do I think this year. There are a lot of precedent actions that we are executing in the first and second quarter. So that that grows can happen later this year since we talked about previously we need to get this I T systems in place and underway will have many benefits so much better customer engagement.
I do something to do business with but it really will enable us to eliminate some of the other we've done that capabilities we have enough.
Sufficient way that we do business today with our legacy systems, which are are quite old and quite a lot of manual workarounds.
He is Ah that's affected as we are so little thing can only really happened first and second quarter, which then gives us the ability to streamline our business in gross sales even more.
Second half and then of course, as we continue coming out with new products in the year, especially with the power wheelchair respiratory products that are kind of come out through your sales will CRE nationally.
The later part of your first quarter as we mentioned that there is on the call. It can be the typical seasonal kind of flat I think second third and fourth quarter should be much more interesting.
You know your other question are part of Islam confidence I think what we're doing this year.
Yes, absolutely within the bandwidth accomplished in the last couple of years and seeing what we did last year with new product innovation, but lack of commercialization of those hence its really already focus this year and meaningful steps to drive growth from new products into seven products, we've got really commercializing, while ensuring the ways to make sure that happened and.
Going to make additional investment and the sale side of the house influence demos to.
I'll try that.
Okay. Thanks, and then finally, just on the E com the convertible debt. So with the actions you took and the fourth quarter third quarter, I guess third and fourth quarter you reduce the outstanding a portion of that first tried to 21, it's doing 20 wonder about 61 million I think so.
What are your plans for the remaining 61 million that's due.
Yes. The number one thing is focused on profitable growth and EBITDA enhances which gives us.
Freezing flexibility and normal commercial banking relations overtime.
In the meantime look opportunistically, if not a miniature cash how to use all the facilities, we have to to manage that hopefully investors. Appreciate that are looking at the state of the actions we took in 2019.
If you then into that no I think that's that's the key is returning to profitable growth and and generating positive cash flow will give us much more options on how to do so.
Okay, great. Thank you.
Thanks, Mike.
And that will take a question from Matthew Michigan with Keybanc.
Great thing, that's going to taking the questions and good morning, everyone on the ones that morning.
Hey, just bear with me on my math them I'm on the West Coast really early right now.
It's as I'm looking at the spacing of EBITDA Threeq is typically your best EBITDA quarter, and if I'm understanding of the run rate correctly, you're thinking that you're exiting the fourth quarter with with $21 billion to $25 billion of EBITDA I mean, just keep it off slot in ER.
And in the first happens in the second half the majority of the vast majority of the EBIT after years generated.
Well I think two things, we're expecting to normal seasonal profile and as you and others will remember.
Quarters in 2019, they're pretty aggressively towards the end of year in the first quarter, we accumulated under $2 million worth of EBITDA by the second quarter, we didn't accumulated four or 5 million and we went from four or 5 million by by June 30, It's just 20.7 by the end of year. So we have a capability to do that.
The seasonality in 2020 should be similar and it's also going to be different in 2020 is you'd start.
Stronger fourth quarters, often some cost savings and new products that are happening earlier in the year. So maybe the third fourth quarter relative balance each other be a little different we expect a pretty strong that passenger.
But you're right I think it's going to you as you see that seasonality in 2019 2020 would have similar seasonality.
Okay.
And as you think about that 2% to 4% gross.
How should we thinking about that like North America versus Europe.
And now that you're giving guidance.
I'm talking about what is what would be the expected FX headwinds in 2020 in Boston.
We continue to expect a reasonably similar constant currency sales growth in Europe, the big change.
This year should be what bias towards north American really bringing both of those regions up to that 2.4% products that we have coming out.
Ended up going global in this year and commercialization efforts are underway in both regions to make sure that they're very effective markets are helping those places probably the biggest incremental increases in north American sitting alongside since you've been at that level.
Revenue growth.
On the FX side of the House you know the euro it's roughly at a one time a range and that really is where our plan is base right now so as long as it stays.
Pretty much in that range wishes he could we do enter into hedge contracts.
Sales as well the cost side of the house to protect the company against FX and those are normally entered into.
The average as I've seen before it would be in Q4 19 rate.
So obviously, we don't have a crystal ball is that where FX is gonna go but.
Right now based on where we see the races. Okay.
The report reported and and organic constant currency growth about about saying.
About the same right now yes.
And then just looking at just looking at the working capital.
What was the driver and I've been and maybe I'm, maybe ever so maybe that I'm just looking at on what was the driver of the $18 million increase in accounts payable.
You're looking at the balance sheet the reported balance yeah. Yeah. Yeah, you can't really look at the reported balance sheet, because there would be FX within it. So if you take a look at our working capital.
For the full year, he would say that the main driver and reductions in inventory.
That's really worry about writing get you can't go off the balance sheet.
[laughter].
And last questions a little bit of a bigger bigger picture question, which is a lot of companies talking about connectivity and data business transformation of digital health. You guys were ahead of this with with links a couple of years ago, where are you out well with links now and our customers, becoming more interested in that and that.
Kinda offering.
Yes, it's an interesting point and we're pleased that has had three years of development in the marketplace. We've got cut even launched in August 20 cents Union, we had the same technology going or how should concentrate is.
Also in 27 team and as we get out and talked to customers about.
In total cost of ownership and making sure that the right modality of their solutions are in the hands as reimbursed clients, that's becoming more and more interesting than more products you have out there that anything I think that's occurred in the last year is probably very cost effective ways.
Okay and product and have been be easily compliant with whatever regulatory regime is in effect in the market. That's being served so we see that expanding across our portfolio in the future and it's been more Sicily links is giving us a really good platform to understand how to do the normal kinds of things that need.
The interesting d. today, not only for end users providers in the clinicians who are working to patients. So that gives us a head start as we've been going forward.
No that's not Kathy well close.
Alright. Thanks.
And Chris cooling with Stephens has next question.
Thank you good morning, I appreciate you taking the questions Chris just a covenant certainly hey, good morning, everyone. Just a couple from me if we could maybe get a little bit more behind the results of respiratory for a course of the fourth quarter.
And then you know use that as a launching pad to think about.
The expectations for growth and this coming year.
I guess, two things specifically I'd like to start with could you.
Maybe help us kind of compare and contrast, the growth in both the people see offering.
It looks maybe at home for without.
Person so traditional constant Twitter business I know you have bundled.
Right exiting the second half of last year, and just kind of curious about what you saw there what you learn from that.
And then how you affect growth going going forward in that category.
On a quick follow up thanks.
Yeah sure you know the respiratory market's been probably the most dynamic market or is it into tier serves over the last few years with changes in reimbursement and strong shifts in different modalities battery powered portable oxygen concentrators important part of our offering we tried to be out there was a solution that is innovative as we think providers.
Yes, and in ways that end users want other certainly a lot of advertising in the world that makes end users, but this is the only solution for ambulatory oxygen. It certainly Britain and we think we have a great will feature product out there I think the since I have a lot of course.
Summers I've talked to worldwide in the last six months is people are starting to providers are starting to realize what im expenses modality that is to have been a rental market.
Let's see so I think people are coming back and looking at home sale, which when you compare the five year tenure operating cost of Homefill system, which gives you into a tory oxygen for more ambulatory breathing time than any.
The equivalent weight, that's battery powered including our own. It also has no vibration no noise and Mohit, it's really a fantastic solution and that total cost at home.
As a minuscule compared to fourth watching Concentrators now that's it there are some places where a portable oxygen concentrator. This based on battery power might be the better solutions, which is why this year we launch.
I think the world truly only hands free device, because now with remote control through a smartphone someone can put it in them in a backpack mode and really have both hands free. So now it's we're up talking to customers worldwide about our respiratory portfolio can inventory solutions. We have you had things that are great.
That are based on.
Homefield solution really low cost really quiet really light weight because it durable.
Solution that it is and they get continuous oxygen flow, which you can't get in a battery power solution and then for those who really want an active lifestyle. We're the only game in town.
So we feel like we're going to have a good ambulatory here in 2020, and then we've done a tremendous amount of work that seem to be done or stationary oxygen concentrate in London.
Huge investments it reliability improvements over the last 18 months, which are reflected in.
What customers are seeing and experiencing and that will lead us to a whole new product line stationary concentrators and twin twinning. So given all that we're in a very very different places, where we were a year ago. When the respiratory was in a substantial declines in North America initially as a result.
Reimbursement changes as a leader as a result of internal changes that need not that she's price.
No cost that really to deliver the best students that we can put out in the marketplace.
Yes, just as a quick follow up to that.
When you realize the value of that proposition I think undeterred bundling your previous was able to build both under 13 Nani for the stationary tank, but also on the Ti Vo C code.
And really what I'm wanting to get out here with the investment that you're thinking in the respiratory side.
How does this change.
Operating margin profile of that business you know as soon as we think about calendar 20, the current year.
And going forward or longer term. Thanks.
Thanks, so much.
Sure.
We are reimbursed enough to our providers, who are experts and reimbursement in their markets and believe we know very well how to how to deal with getting seems reimbursement.
And that's a deferred.
Market specific experts on that but I think the margin in our business despite being substantially smaller than the last year, it's incredibly better.
Due to cost savings and really focusing on reliable solutions that stand up in the marketplace, that's going to really big durable driver of improvements in respiratory business. We came into 2019 without a lot of optimism in the respiratory business, which means we didn't hold on to any fringe costs that might have been supported by really come back and revenue.
We really took it all out and put a lot of technical innovation into the unit.
I found principles that is up making a big change, but I think knows market, we see the reliability of those products to customers are seen already so that's helped margins and that should propel us into next year as providers don't always look at the low price. They want the lowest total cost of ownership and we can demonstrators that justify the difference.
Thank you very much.
Right. Thanks, Chris.
What about ladies and gentlemen, this will conclude your question in that professional turn the call back to your host for closing remarks.
Thanks, Jay can takes everything for their Tenda decision on todays call Kathy Lewis and I are available for follow up questions throughout the world.
Good day.
And ladies and gentlemen, this does conclude your conference for today. Thank you for your participation you may now disconnect.
[music].
Oh.
Oh.
[noise].
Oh.
[noise].